Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts

Anti-Cancer Drugs

Volumn 19, Issue 7, 2008, Pages 721-727

  Staffhorst, Rutger W H M ^a   Van Der Born, Kasper ^b   Erkelens, Caroline A M ^b   Hamelers, Irene H L ^a   Peters, Godefridus J ^b   Boven, Epie ^b   De Kroon, Anton I P M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biodistribution; Cisplatin; Drug delivery; Lipid formulation; Nanocapsules; Ovarian carcinoma xenograft

Indexed keywords

CISPLATIN; NANOCAPSULE; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG LIVER LEVEL; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN CELL; KIDNEY; LUNG; MAXIMUM TOLERATED DOSE; MOUSE; NANOENCAPSULATION; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PRIORITY JOURNAL; SPLEEN; TUMOR XENOGRAFT; ANIMAL; DRUG SCREENING; OVARY TUMOR; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; HUMANS; MICE; MICE, NUDE; NANOCAPSULES; OVARIAN NEOPLASMS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 51049084908     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328304355f     Document Type: Article

References (35)

1. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4:307-320.
2. Akaboshi M, Kawai K, Maki H, Akuta K, Ujeno Y, Miyahara T. The number of platinum atoms binding to DNA, RNA and protein molecules of HeLa cells treated with cisplatin at its mean lethal concentration. Jpn J Cancer Res 1992; 83:522-526.
3. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 2001; 59:657-663.
4. Cvitkovic E. Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat Rev 1998; 24:265-281.
5. Reedijk J. Why does cisplatin reach guanine-n7 with competing s-donor ligands available in the cell? Chem Rev 1999; 99:2499-2510.
6. Giaccone G. Clinical perspectives on platinum resistance. Drugs 2000; 59 (Suppl 4):9-17.
7. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 1999; 43:1-7.
8. Boulikas T. Low toxicity and anticancer activity of a novel liposomal cisplatin (lipoplatin) in mouse xenografts. Oncol Rep 2004; 12:3-12.
9. Vaage J, Donovan D, Wipff E, Abra R, Colbern G, Uster P, et al. Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes. Int J Cancer 1999; 80:134-137.
10. Veal GJ, Griffin MJ, Price E, Parry A, Dick GS, Little MA, et al. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. Br J Cancer 2001; 84:1029-1035.
11. Harrington KJ, Lewanski CR, Northcote AD, Whittaker J, Wellbank H, Vile RG, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol 2001; 12: 493-496.
12. Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M. Systemic lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res 2005; 25:3031-3039.
13. Wittgen BP, Kunst PW, van der Born K, van Wijk AW, Perkins W, Pilkiewicz FG, et al. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res 2007; 13:2414-2421.
14. Meerum Terwogt JM, Groenewegen G, Pluim D, Maliepaard M, Tibben MM, Huisman A, et al. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol 2002; 49:201-210.
15. Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Zuhowski EG, Pluim D, et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 2004; 53:329-336.
16. Bandak S, Goren D, Horowitz A, Tzemach D, Gabizon A. Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs 1999; 10:911-920.
17. Burger KN, Staffhorst RW, de Vijlder HC, Velinova MJ, Bomans PH, Frederik PM, et al. Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat Med 2002; 8:81-84.
18. Chupin V, de Kroon AI, de Kruijff B. Molecular architecture of nanocapsules, bilayer-enclosed solid particles of cisplatin. J Am Chem Soc 2004; 126:13816-13821.
19. de Kroon AI, Staffhorst RW, de Kruijff B, Burger KN. Cisplatin nanocapsules. Methods Enzymol 2005; 391:118-125.
20. Velinova MJ, Staffhorst RW, Mulder WJ, Dries AS, Jansen BA, de Kruijff B, et al. Preparation and stability of lipid-coated nanocapsules of cisplatin: anionic phospholipid specificity. Biochim Biophys Acta 2004; 1663: 135-142.
21. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992; 1113:171-199.
22. Burger KN, Staffhorst RW, de Kruijff B. Interaction of the anti-cancer drug cisplatin with phosphatidylserine in intact and semi-intact cells. Biochim Biophys Acta 1999; 1419:43-54.
23. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, et al. United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer 1998; 77:1-10.
24. Treskes M, Boven E, Holwerda U, Pinedo HM, van der Vijgh WJ. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. Cancer Res 1992; 52:2257-2260.
25. Van Moorsel CJ, Pinedo HM, Smid K, Comijn EM, Voorn DA, Veerman G, et al. Schedule dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis Lung murine non-small cell lung tumors. Eur J Cancer 2000; 36:2420-2429.
26. Kolfschoten GM, Pinedo HM, Scheffer PG, Schluper HM, Erkelens CA, Boven E. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. Gynecol Oncol 2000; 76:362-368.
27. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51:691-743.
28. Scherphof GL, Kamps JA. The role of hepatocytes in the clearance of liposomes from the blood circulation. Prog Lipid Res 2001; 40:149-166.
29. Liu D, Mori A, Huang L. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta 1992; 1104:95-101.
30. Senior J, Crawley JC, Gregoriadis G. Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection. Biochim Biophys Acta 1985; 839:1-8.
31. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1991; 1068: 133-141.
32. Kim J-H, Kim Y-S, Park K, Lee S, Nam HY, Min KH, et al. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Control Release 2008; 127:41-49.
33. Tokuda K, Natsugoe S, Shimada M, Kumanohoso T, Baba M, Takao S, et al. Design and testing of a new cisplatin form using a base material by combining poly-D,L-lactic acid and polyethylene glycol acid against peritoneal metastasis. Int J Cancer 1998; 76:709-712.
34. Xu P, Van Kirk EA, Murdoch WJ, Zhan Y, Isaak DD, Radosz M, et al. Anticancer efficacies of cisplatin-releasing pH-responsive nanoparticles. Biomacromolecules 2006; 7:829-835.
35. Hamelers IH, van Loenen E, Staffhorst RW, de Kruijff B, de Kroon AI. Carboplatin nanocapsules: a highly cytotoxic, phospholipid-based formulation of carboplatin. Mol Cancer Ther 2006; 5:2007-2012.